
Merck (MRK) announced the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan, an investigational TROP2-directed antibody-drug conjugate licensed from Kelun-Biotech, met its primary endpoint of overall survival compared to treatment
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| MRK | Merck & Company | 133.72 | 38.75 | 40.80% |
| Name | Price | % Change | |
|---|---|---|---|
| $133.72 | +40.80% |

Merck (MRK) announced the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan, an investigational TROP2-directed antibody-drug conjugate licensed from Kelun-Biotech, met its primary endpoint of overall survival compared to treatment

Halozyme (HALO) provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck (MRK) to refrain from distributing and offering Keytruda SC

Merck (MRK) and Isomorphic Labs, an AI-first drug design and development company, announced a research collaboration that brings together Isomorphic Labs’ AI approach to drug discovery with Merck’s proprietary data

Merck & Company ( ($MRK) ) has provided an announcement. On Nov. 16, 2026, Thomas H. Glocer notified Merck of his intention to retire from its board at the May

Merck (MRK) announced that Thomas Glocer intends to retire from the Merck Board of Directors at the company’s Annual Meeting of Shareholders in May 2027. The independent members of the

Merck (MRK) announced the discontinuation of the clinical development program evaluating nemtabrutinib, an investigational, oral, non-covalent Bruton’s tyrosine kinase inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia,

Monday was another rough day for the major indexes. On the other hand, it was a pretty good day for the consumer staples sector. Consider that the S&P 500 is

Exchange-traded funds (ETFs) offer investors broad exposure to leading companies through a single route. However, the market is crowded with thousands of them. TipRanks’ AI analyst recommends the following ETFs

Merck (MRK), known as MSD outside of the U.S. and Canada, announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA,

Merck (MRK), known as MSD outside of the U.S. and Canada, announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA,
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Assigned | Nov 19, 2026 | ||||
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| hold | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| hold | Reiterated | Nov 5, 2026 | ||||
| hold | Downgraded | Nov 3, 2026 | ||||
| hold | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 2, 2027Before Open | $327.41B | $1.74 | $16.29B | 1.81 | 135.07 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.